Emily V Dressler1, Meng Liu2, Catherine R Garcia3, Therese A Dolecek4, Thomas Pittman5, Bin Huang2, John L Villano6,7,5,3. 1. Department of Biostatistical Sciences, School of Medicine Wake Forest School of Medicine, Winston Salem, NC. 2. Division of Cancer Biostatistics, University of Kentucky, Lexington, Kentucky. 3. Markey Cancer Center, University of Kentucky, Lexington, Kentucky. 4. University of Kentucky, Lexington, Kentucky; Division of Epidemiology and Biostatistics and Institute for Health Research and Policy, School of Public Health, University of Illinois at Chicago, Chicago, Illinois. 5. Department of Neurosurgery, University of Kentucky, Lexington, Kentucky. 6. Department of Medicine, University of Kentucky, Lexington, Kentucky. 7. Department of Neurology, University of Kentucky, Lexington, Kentucky.
Abstract
BACKGROUND: Glioblastoma is an aggressive disease with a defined standard of care offering crucial survival benefits. Disparities in care may influence treatment decisions. This study seeks to evaluate potential patterns in care delivery using the National Cancer Database (NCDB). METHODS: We evaluated the NCDB from 1998 to 2011 for patients diagnosed with glioblastoma older than 20 years of age in order to describe current hospital-based demographics, rates of treatment modality by age, race, gender, likelihood of receiving treatment, and survival probabilities. RESULTS: From 1998 to 2011, 100672 patients were diagnosed with glioblastoma in the United States. Of these, 54% were younger than 65 years of age, while 20% were 75 years of age or older. The most common type of treatment was surgery (73%), followed by radiation (69%) and chemotherapy (50%). Eleven percent of patients did not receive any form of therapy. Patients receiving no form of treatment were more likely to be older, female, black, or Hispanic. Tumors that did not involve brainstem, ventricles, or the cerebellum were associated with more aggressive treatment and better overall survival. The median survival was 7.5 months. The use of concomitant surgical resection, chemotherapy, and radiation demonstrated greater survival benefit. CONCLUSIONS: Median survival for glioblastoma is significantly less than reported in clinical trials. Sociodemographic factors such as age, gender, race, and socioeconomic status affect treatment decisions for glioblastoma. The elderly are greatly undertreated, as many elderly patients receive no treatment or significantly less than standard of care.
BACKGROUND: Glioblastoma is an aggressive disease with a defined standard of care offering crucial survival benefits. Disparities in care may influence treatment decisions. This study seeks to evaluate potential patterns in care delivery using the National Cancer Database (NCDB). METHODS: We evaluated the NCDB from 1998 to 2011 for patients diagnosed with glioblastoma older than 20 years of age in order to describe current hospital-based demographics, rates of treatment modality by age, race, gender, likelihood of receiving treatment, and survival probabilities. RESULTS: From 1998 to 2011, 100672 patients were diagnosed with glioblastoma in the United States. Of these, 54% were younger than 65 years of age, while 20% were 75 years of age or older. The most common type of treatment was surgery (73%), followed by radiation (69%) and chemotherapy (50%). Eleven percent of patients did not receive any form of therapy. Patients receiving no form of treatment were more likely to be older, female, black, or Hispanic. Tumors that did not involve brainstem, ventricles, or the cerebellum were associated with more aggressive treatment and better overall survival. The median survival was 7.5 months. The use of concomitant surgical resection, chemotherapy, and radiation demonstrated greater survival benefit. CONCLUSIONS: Median survival for glioblastoma is significantly less than reported in clinical trials. Sociodemographic factors such as age, gender, race, and socioeconomic status affect treatment decisions for glioblastoma. The elderly are greatly undertreated, as many elderly patients receive no treatment or significantly less than standard of care.
Entities:
Keywords:
Glioblastoma; patterns of care; survival; treatment
Authors: Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan Journal: J Neurooncol Date: 2007-05-26 Impact factor: 4.130
Authors: Susan M Chang; Ian F Parney; Wei Huang; Frederick A Anderson; Anthony L Asher; Mark Bernstein; Kevin O Lillehei; Henry Brem; Mitchel S Berger; Edward R Laws Journal: JAMA Date: 2005-02-02 Impact factor: 56.272
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert Journal: Brain Date: 2007-09-04 Impact factor: 13.501
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Michael Youssef; Ethan B Ludmir; Jacob J Mandel; Akash J Patel; Ali Jalali; Jeffrey Treiber; Jimin Wu; Mary Frances McAleer; John F de Groot Journal: J Neurooncol Date: 2019-10-23 Impact factor: 4.130
Authors: Luc Bauchet; Jacques Guyotat; Thiébaud Picart; David Meyronet; Johan Pallud; Chloé Dumot; Philippe Metellus; Sonia Zouaoui; Moncef Berhouma; François Ducray Journal: J Cancer Res Clin Oncol Date: 2021-01-05 Impact factor: 4.553
Authors: Catherine R Garcia; Zin W Myint; Rani Jayswal; Chi Wang; Rachael M Morgan; Allison R Butts; Heidi L Weiss; John L Villano Journal: J Neurooncol Date: 2021-11-24 Impact factor: 4.130
Authors: Victor M Lu; Daniel G Eichberg; Evan M Luther; Ashish H Shah; David J Daniels; Ossama M Maher; Toba N Niazi Journal: Childs Nerv Syst Date: 2021-10-13 Impact factor: 1.475